Funding profile · Surgical robotics

Revolve Surgical

A Canadian surgical robotics company with an FDA clearance and almost no disclosed capital. There is no Form D, because there is no US offering on record. What exists is three commercial databases that disagree.

$125KTotal raised to date, one round, per Tracxn
$244KTotal raised across 8 deals, per PitchBook
$0Disclosed in SEC filings. No Form D, no EDGAR entity
14Investors counted by PitchBook, of which 5 are named

Data as of September 22, 2026. Company-reported and vendor-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Mar 2021 Accelerator, then a grant Not disclosed Not named PitchBook
Jul 2021 Seed Not disclosed Not named PitchBook
Sep 1, 2021 Y Combinator, Summer 2021 $125,000 per Tracxn Y Combinator Tracxn, YC
Sep 2021 Seed Not disclosed Not named PitchBook
Apr 2024 Accelerator Not disclosed Not named PitchBook
Jan 15, 2026 MassRobotics Healthcare Robotics Startup Catalyst, 5th cohort Not disclosed MassRobotics, with Novanta Company post
All deals Named backers Not disclosed Y Combinator, MassRobotics, Innovation Factory (Hamilton), Asymmetry Ventures, Mentors Fund PitchBook

What the filings show

SEC EDGAR · no filing of any kind

Form D
None
Registrant
No EDGAR company matches Revolve Surgical
Full text search
Zero documents, all form types, all dates
Why
A Canadian issuer selling to Canadian investors files nothing here
Checked
Sep 22, 2026

FDA · 510(k) K243968 · cleared Oct 3, 2025

Applicant
Revolve Surgical, Inc., 619-2 Carlton Street, Toronto
Signed by
Alex Gordon, Chief Executive Officer
Received
Dec 23, 2024 · amended Sep 5, 2025
Class
II · 21 CFR 876.1500 · code GCJ
Predicate
HX Device, Human Xtensions (K173919)
Announced
Mar 17, 2026, five and a half months later

Health Canada · MDALL · no licence

Company search
Revolve returns an empty result
Control
The same search for Intuitive returns Intuitive Surgical Inc.
Device search
No licence named Revolve Surgical
Context
The Toronto study calls the system investigational
Checked
Sep 22, 2026

Reading the filings

  1. The absence of a Form D is not a red flag.A full text search of EDGAR returns zero documents across all form types, and no EDGAR company record exists. Form D covers offerings sold under Regulation D, and an Ontario company raising from Canadian and accelerator sources has no reason to file one. Every capital figure here comes from a commercial database, not a filing.
  2. Three databases, three totals.Tracxn says $125K in one round, CB Insights $130K, PitchBook $244K across eight deals. The $119,000 spread is about one accelerator cheque, so the disagreement is about how many accelerator and grant entries each vendor counts, not a missing venture round.
  3. Five of the eight recorded deals are not priced financings.PitchBook logs four accelerator entries and one grant against two seeds in 2021. The January 2026 accelerator matches the MassRobotics cohort the company announced itself. That is a company funded by programs, not by rounds.
  4. The clearance arrived before the money.The FDA decision is dated October 3, 2025, and the only capital event on record after it is an accelerator cohort. No priced round has been reported since, and the company still lists a team of eight.
  5. The peer set is orders of magnitude larger.Tracxn ranks Revolve 92nd among 238 active competitors and puts CMR Surgical at $1.28B raised, PROCEPT BioRobotics at $349M and Medical Microinstruments at $210M. Distalmotion, chasing the same ambulatory surgery centers, has taken about $400M. On Tracxn numbers, Revolve has raised roughly one ten thousandth of CMR.
  6. The board is the founders.Tracxn lists three current board members: Matthew Kang, Peter Francis and Peter Alexander Gordon, all marked independent and all founders. No investor director appears anywhere in the public record, which fits a company that has taken no priced institutional round.

Commercial signals

Signal Detail Source type
Regulatory FDA 510(k) K243968, cleared Oct 3, 2025 for general surgery. One reusable table mounted arm and a straight, single action needle holder through a 5mm trocar. Wristed instruments and AI are not cleared. Public record
Clinical NCT07455487, three appendectomies at Unity Health Toronto, first in human, still not yet recruiting. Public record
Canada No Health Canada device licence on the active listing. Not found
Revenue None reported. No pricing, no named customers, no commercial launch. Not found
Intellectual property PitchBook lists five publications from two families, filed Mar 2022 and Feb 2023, with national phase filings in Australia, Europe and Japan. CB Insights counts four filed, one granted Sep 9, 2025. Data provider
Programs Y Combinator Summer 2021, Creative Destruction Lab, Innovation Factory, OBIO CAAP, MassRobotics 2026 cohort. Company and partner stated

What to watch

  • A first priced round. Eleven months since the clearance, no financing reported.
  • A Form D, which appears only if the company sells into the United States under Regulation D.
  • The three patient Toronto series, and whether the April 2026 start date holds.
  • A second 510(k) covering all laparoscopic surgery, which the company expects before launch.
  • A Health Canada licence, without which the home market stays closed.

The Revolve Surgical story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Clear Gene: Shared investor: Asymmetry Ventures. An RNA test built to tell a surgeon whether the whole tumor came out
  • SFA Therapeutics: Shared investor: Asymmetry Ventures. A Temple University spinout turning short chain fatty acids from the human gut into oral pills
  • Persist AI: Shared investor: Asymmetry Ventures. A robotic laboratory in West Sacramento that builds and tests long acting injectable formulations by the hundred, rented to drug companies through a web browser
  • Rejuvenation Technologies: Shared investor: Asymmetry Ventures. A Stanford spinout that switches telomerase on for a day or two with modified mRNA, then lets it fade

Sources

  1. Public recordSEC EDGAR full text and company searchSEC · Sep 22, 2026
  2. Public recordFDA 510(k) clearance letter and 510(k) summary, K243968FDA · Oct 3, 2025
  3. Public recordHealth Canada active licence listing queriesHealth Canada · Sep 22, 2026
  4. Public recordClinicalTrials.gov NCT07455487Unity Health Toronto · first posted Mar 6, 2026
  5. Data providerRevolve Surgical company profile, funding and boardTracxn · accessed Sep 22, 2026
  6. Data providerRevolve Surgical deal history, investors and patentsPitchBook · accessed Sep 22, 2026
  7. Data providerRevolve Surgical total raised and patent countCB Insights · accessed Sep 22, 2026
  8. IndependentSurgeries are moving to ASCs. Distalmotion wants its robot to drive the shift.Healthcare Dive, Susan Kelly · Apr 29, 2026
  9. IndependentRevolve Surgical wins FDA clearance for surgical robotMassDevice, Sean Whooley · Mar 17, 2026
  10. CompanyCompany page, FDA clearance and MassRobotics cohort postsLinkedIn · accessed Sep 22, 2026

Compiled from SEC, FDA, Health Canada and ClinicalTrials.gov public records, commercial data providers and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; none exists for this company, and its absence is not evidence that no capital was raised. Healthcare Venture Capital Fund holds no position in Revolve Surgical. This page is not an offer to sell or a recommendation to buy any security.